Einzeltreffer — DigiBib

Osteoporosis represents a systemic imbalance in bone metabolism, augmenting the susceptibility to fractures among patients and emerging as a notable mortality determinant in the elderly population. It has evolved into a worldwide concern impacting the physical well-being of the elderly, imposing a substantial burden on both human society and the economy. Presently, the precise pathogenesis of osteoporosis remains inadequately characterized and necessitates further exploration. The advancement of osteoporosis is typically linked to the initiation of an inflammatory response. Cells in an inflammatory environment can cause inflammatory death including pyroptosis. Pyroptosis is a recently identified form of programmed cell death with inflammatory properties, mediated by the caspase and gasdermin families. It is regarded as the most inflammatory form of cell death in contemporary medical research. Under the influence of diverse cytokines, macrophages, and other immune cells may undergo pyroptosis, releasing inflammatory factors, such as IL-1β and IL-18. Numerous lines of evidence highlight the pivotal role of pyroptosis in the pathogenesis of inflammatory diseases, including cancer, intestinal disorders, hepatic conditions, and cutaneous ailments. Osteoporosis progression is frequently associated with inflammation; hence, pyroptosis may also play a role in the pathogenesis of osteoporosis to a certain extent, making it a potential target for treatment. This paper has provided a comprehensive summary of pertinent research concerning pyroptosis and its impact on osteoporosis. The notion proposing that pyroptosis mediates osteoporosis via the inflammatory immune microenvironment is advanced, and we subsequently investigate potential targets for treating osteoporosis through the modulation of pyroptosis.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Titel:	Pyroptosis mediates osteoporosis via the inflammation immune microenvironment.
Autor/in / Beteiligte Person:	Chen, T ; Jin, L ; Li, J ; Liu, Y
Link:	Full Text Finder (Volltext)
Zeitschrift:	Frontiers in immunology, Jg. 15 (2024-06-03), S. 1371463
Veröffentlichung:	[Lausanne : Frontiers Research Foundation], 2024
Medientyp:	academicJournal
ISSN:	1664-3224 (electronic)
DOI:	10.3389/fimmu.2024.1371463
Schlagwort:	Humans Animals Cellular Microenvironment immunology Pyroptosis immunology Osteoporosis immunology Osteoporosis metabolism Osteoporosis etiology Inflammation immunology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Front Immunol] 2024 Jun 03; Vol. 15, pp. 1371463. <i>Date of Electronic Publication: </i>2024 Jun 03 (<i>Print Publication: </i>2024). MeSH Terms: Pyroptosis* / immunology ; Osteoporosis* / immunology ; Osteoporosis* / metabolism ; Osteoporosis* / etiology ; Inflammation* / immunology ; Humans ; Animals ; Cellular Microenvironment / immunology References: Biochem Biophys Res Commun. 2017 Mar 18;484(4):871-877. (PMID: 28167279) ; Mol Med Rep. 2020 Oct;22(4):3299-3306. (PMID: 32945495) ; Pharmacol Ther. 2018 Jul;187:133-149. (PMID: 29466702) ; J Clin Invest. 2013 Jan;123(1):394-404. (PMID: 23221342) ; Mediators Inflamm. 2015;2015:782382. (PMID: 25954061) ; J Endocrinol Invest. 1990 Sep;13(8):625-30. (PMID: 2273204) ; Physiol Rep. 2024 Jan;12(1):e15914. (PMID: 38217044) ; Physiol Int. 2022 Feb 28;:. (PMID: 35230263) ; Planta Med. 2021 Apr;87(4):273-282. (PMID: 33285594) ; Physiol Rev. 2001 Oct;81(4):1535-65. (PMID: 11581496) ; Exp Cell Res. 2021 Nov 1;408(1):112814. (PMID: 34492267) ; Steroids. 2013 May;78(5):513-20. (PMID: 23499826) ; Nature. 2017 Jul 6;547(7661):99-103. (PMID: 28459430) ; Endocr Pract. 2020 May;26(Suppl 1):1-46. (PMID: 32427503) ; Curr Drug Targets. 2020;21(3):213-227. (PMID: 31433756) ; Calcif Tissue Int. 2018 Oct;103(4):400-410. (PMID: 29804160) ; Oxid Med Cell Longev. 2021 Nov 3;2021:4139048. (PMID: 34777685) ; Dev Cell. 2022 Oct 24;57(20):2365-2380.e8. (PMID: 36243012) ; Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1498-1507. (PMID: 31255720) ; Adv Sci (Weinh). 2023 Jul;10(19):e2207383. (PMID: 37204068) ; J Clin Pathol. 2008 May;61(5):577-87. (PMID: 18441154) ; J Bone Miner Metab. 2021 Jul;39(4):547-557. (PMID: 33566209) ; Cells. 2020 Apr 10;9(4):. (PMID: 32290085) ; MedComm (2020). 2023 May 11;4(3):e244. (PMID: 37188325) ; Eur J Pharmacol. 2022 Aug 5;928:175091. (PMID: 35714692) ; Genomics. 2024 Jan;116(1):110769. (PMID: 38141931) ; Ann N Y Acad Sci. 2006 Apr;1068:256-74. (PMID: 16831927) ; J Cell Mol Med. 2023 Nov;27(22):3601-3613. (PMID: 37621124) ; Nature. 2022 Feb;602(7897):496-502. (PMID: 35110732) ; Nat Med. 2015 Mar;21(3):248-55. (PMID: 25686105) ; Theranostics. 2022 May 16;12(9):4310-4329. (PMID: 35673561) ; Cells. 2022 Dec 06;11(23):. (PMID: 36497201) ; Cell. 2000 Jul 7;102(1):33-42. (PMID: 10929711) ; Trends Mol Med. 2021 Sep;27(9):856-867. (PMID: 34312075) ; Nat Rev Immunol. 2017 Mar;17(3):151-164. (PMID: 28138137) ; Cancer Lett. 2018 Apr 10;419:8-19. (PMID: 29339210) ; Exp Cell Res. 2009 Apr 15;315(7):1287-301. (PMID: 19331827) ; Nat Rev Mol Cell Biol. 2020 Nov;21(11):678-695. (PMID: 32873928) ; Joints. 2018 Jun 14;6(2):122-127. (PMID: 30051110) ; Mediators Inflamm. 2022 Nov 23;2022:2581151. (PMID: 36466156) ; Science. 2020 May 29;368(6494):. (PMID: 32299851) ; Curr Opin Immunol. 2018 Feb;50:32-38. (PMID: 29128729) ; Mediators Inflamm. 2019 Sep 8;2019:2165918. (PMID: 31582897) ; Ann Transl Med. 2019 Apr;7(8):170. (PMID: 31168451) ; J Ethnopharmacol. 2022 Jul 15;293:115269. (PMID: 35398497) ; Am J Pathol. 2020 Feb;190(2):272-285. (PMID: 31783008) ; Front Immunol. 2018 Apr 05;9:657. (PMID: 29675022) ; Am J Physiol Endocrinol Metab. 2013 Jul 1;305(1):E15-21. (PMID: 23592480) ; Sci Rep. 2016 Sep 21;6:33680. (PMID: 27649785) ; Trends Mol Med. 2021 Jul;27(7):687-699. (PMID: 34030963) ; Small. 2020 Jan;16(1):e1905977. (PMID: 31814281) ; J Cell Mol Med. 2023 Dec;27(24):4093-4106. (PMID: 37830762) ; Diabetes. 2022 Dec 1;71(12):2777-2792. (PMID: 35802043) ; Best Pract Res Clin Rheumatol. 2009 Dec;23(6):769-79. (PMID: 19945688) ; Curr Med Chem. 2020;27(37):6356-6372. (PMID: 31362684) ; Eur J Rheumatol. 2017 Mar;4(1):46-56. (PMID: 28293453) ; Int Immunopharmacol. 2023 Nov;124(Pt B):110901. (PMID: 37839278) ; Mil Med Res. 2022 Aug 23;9(1):46. (PMID: 35996168) ; Pharmacol Res. 2021 Dec;174:105967. (PMID: 34740817) ; Dev Cell. 2021 Apr 5;56(7):906-918. (PMID: 33689692) ; Ageing Res Rev. 2022 Jun;78:101635. (PMID: 35483626) ; J Dent Res. 2020 Oct;99(11):1287-1295. (PMID: 32531176) ; Inflammation. 2017 Dec;40(6):1933-1943. (PMID: 28766178) ; Curr Opin Immunol. 2015 Feb;32:78-83. (PMID: 25621708) ; Nat Rev Cancer. 2002 Sep;2(9):647-56. (PMID: 12209154) ; Front Immunol. 2021 Feb 04;11:625034. (PMID: 33613566) ; Nature. 2015 Oct 29;526(7575):660-5. (PMID: 26375003) ; Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7829-34. (PMID: 10869427) ; EMBO J. 2016 Aug 15;35(16):1766-78. (PMID: 27418190) ; Clin Transl Med. 2021 Aug;11(8):e492. (PMID: 34459122) ; Nature. 2016 Jul 7;535(7610):111-6. (PMID: 27281216) ; Oral Dis. 2024 Apr;30(3):1392-1402. (PMID: 37004144) ; Obstet Gynecol Surv. 1992 Jan;47(1):38-44. (PMID: 1734333) ; Physiology (Bethesda). 2014 Sep;29(5):325-33. (PMID: 25180262) ; Int J Mol Sci. 2022 May 29;23(11):. (PMID: 35682777) ; Nat Cell Biol. 2020 Oct;22(10):1264-1275. (PMID: 32929201) ; J Clin Invest. 1992 Dec;90(6):2434-8. (PMID: 1469095) ; J Bone Miner Res. 2014 Nov;29(11):2520-6. (PMID: 24771492) ; Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479) ; J Midlife Health. 2023 Jul-Sep;14(3):153-158. (PMID: 38312763) ; Biofactors. 2022 Jan;48(1):22-55. (PMID: 34919768) ; FASEB J. 2015 Apr;29(4):1269-79. (PMID: 25477279) ; Nat Rev Immunol. 2016 Jul;16(7):407-20. (PMID: 27291964) ; Front Endocrinol (Lausanne). 2022 Sep 26;13:962968. (PMID: 36225200) ; J Periodontal Res. 2022 Jun;57(3):448-460. (PMID: 35141913) ; Nature. 2019 Nov;575(7784):679-682. (PMID: 31723262) ; Biochem Biophys Rep. 2023 Jun 10;35:101496. (PMID: 37332667) ; Semin Cell Dev Biol. 2022 Mar;123:14-21. (PMID: 34024716) ; Biochem Biophys Res Commun. 2020 Feb 5;522(2):471-478. (PMID: 31780258) ; Physiol Rev. 2017 Jan;97(1):135-187. (PMID: 27807202) Contributed Indexing: Keywords: bone metabolism; inflammatory factor; inflammatory immune microenvironment; osteoporosis; pyroptosis Entry Date(s): Date Created: 20240619 Date Completed: 20240619 Latest Revision: 20240625 Update Code: 20240626 PubMed Central ID: PMC11184911

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Pyroptosis mediates osteoporosis via the inflammation immune microenvironment.